We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The system supports SPECT imaging and emerging tracers, including Actinium-225 and Lead-212.
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced that it is taking its next-generation StarGuide GX digital 4D cadmium zinc telluride (CZT) SPECT/CT system closer to the U.S. market with the submission to the FDA for 510(k) clearance. Following its recent CE Mark, the milestone marks continued progress toward expanding access to next-generation molecular imaging technologies and supporting a broader range of nuclear medicine applications.
Per Jean-Luc Procaccini, president and CEO, Molecular Imaging and Computed Tomography, GE HealthCare, the company is focused on innovation that anticipates the evolving needs of healthcare and provides clinicians with advanced technologies. With StarGuide GX now 510(k) pending in the United States and CE-Marked in Europe, GEHC is advancing next-generation molecular imaging solutions to support the expansion of theranostics and precision care. The technology is designed to help clinicians adopt emerging tracers, broaden clinical applications and deliver more personalized patient care.
GEHC Stock Trend Following the News
Following the announcement, GEHC stock lost 3% at yesterday’s close. Year to date, shares of the company have fallen 18.6% compared with the industry’s 20.6% decline. However, the S&P 500 has risen 11.6% in the same timeframe.
The regulatory progress of StarGuide GX could strengthen GE HealthCare’s position in the growing molecular imaging market as demand for theranostics and precision medicine continues to expand. Its ability to support both general-purpose SPECT imaging and emerging tracers, including alpha emitters, could create additional opportunities for GEHC as nuclear medicine departments adopt advanced imaging technologies.
GEHC currently has a market capitalization of $31.10 billion.
Image Source: Zacks Investment Research
More on StarGuide GX
StarGuide GX is designed to support the evolving theranostics landscape, where imaging plays an important role in therapy planning, dosimetry, treatment monitoring and clinical research. The system can image across a broad spectrum of energy levels, aiming to support both established SPECT applications and investigational radioligand therapy isotopes.
The system incorporates GE HealthCare’s patented dual-sided CZT detector technology, which is designed to deliver double-volume sensitivity while maintaining high-resolution imaging. The technology aims to enable clinicians to capture more information with shorter scan times. NVIDIA RTX computing is also integrated to support faster image reconstruction and accelerate time to results.
StarGuide GX features a patented dual-collimator detector designed to enable collimator exchange in less than three seconds. The automated exchange capability aims to streamline nuclear medicine workflows by reducing traditional exchange procedures and eliminating the need for multiple collimators, carts and additional storage space.
The system is particularly positioned to address growing interest in alpha-emitting isotopes such as Actinium-225 and Lead-212. As the pipeline of radioligand therapies develops, the ability to accurately image and quantify emerging tracers could become increasingly important for treatment planning, response monitoring and research.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global molecular imaging market is predicted to be valued at $9.5 billion in 2026 and is expected to witness a CAGR of 4.6% through 2030.
Factors like the increasing prevalence of cancer, cardiovascular diseases and neurological disorders, technological advancements and rising investment in research and development are boosting the market’s growth.
Other News
GE HealthCare recently announced that its Photonova Spectra advanced photon-counting computed tomography system has received CE Mark, expanding access to the technology across Europe and other CE Mark-observing markets.
GE HealthCare also announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid Explorer, Vivid Advanced and Vivid Focus — designed to support cardiac imaging and workflow needs across different care settings.
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently sporting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance
Key Takeaways
GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced that it is taking its next-generation StarGuide GX digital 4D cadmium zinc telluride (CZT) SPECT/CT system closer to the U.S. market with the submission to the FDA for 510(k) clearance. Following its recent CE Mark, the milestone marks continued progress toward expanding access to next-generation molecular imaging technologies and supporting a broader range of nuclear medicine applications.
Per Jean-Luc Procaccini, president and CEO, Molecular Imaging and Computed Tomography, GE HealthCare, the company is focused on innovation that anticipates the evolving needs of healthcare and provides clinicians with advanced technologies. With StarGuide GX now 510(k) pending in the United States and CE-Marked in Europe, GEHC is advancing next-generation molecular imaging solutions to support the expansion of theranostics and precision care. The technology is designed to help clinicians adopt emerging tracers, broaden clinical applications and deliver more personalized patient care.
GEHC Stock Trend Following the News
Following the announcement, GEHC stock lost 3% at yesterday’s close. Year to date, shares of the company have fallen 18.6% compared with the industry’s 20.6% decline. However, the S&P 500 has risen 11.6% in the same timeframe.
The regulatory progress of StarGuide GX could strengthen GE HealthCare’s position in the growing molecular imaging market as demand for theranostics and precision medicine continues to expand. Its ability to support both general-purpose SPECT imaging and emerging tracers, including alpha emitters, could create additional opportunities for GEHC as nuclear medicine departments adopt advanced imaging technologies.
GEHC currently has a market capitalization of $31.10 billion.
Image Source: Zacks Investment Research
More on StarGuide GX
StarGuide GX is designed to support the evolving theranostics landscape, where imaging plays an important role in therapy planning, dosimetry, treatment monitoring and clinical research. The system can image across a broad spectrum of energy levels, aiming to support both established SPECT applications and investigational radioligand therapy isotopes.
The system incorporates GE HealthCare’s patented dual-sided CZT detector technology, which is designed to deliver double-volume sensitivity while maintaining high-resolution imaging. The technology aims to enable clinicians to capture more information with shorter scan times. NVIDIA RTX computing is also integrated to support faster image reconstruction and accelerate time to results.
StarGuide GX features a patented dual-collimator detector designed to enable collimator exchange in less than three seconds. The automated exchange capability aims to streamline nuclear medicine workflows by reducing traditional exchange procedures and eliminating the need for multiple collimators, carts and additional storage space.
The system is particularly positioned to address growing interest in alpha-emitting isotopes such as Actinium-225 and Lead-212. As the pipeline of radioligand therapies develops, the ability to accurately image and quantify emerging tracers could become increasingly important for treatment planning, response monitoring and research.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global molecular imaging market is predicted to be valued at $9.5 billion in 2026 and is expected to witness a CAGR of 4.6% through 2030.
Factors like the increasing prevalence of cancer, cardiovascular diseases and neurological disorders, technological advancements and rising investment in research and development are boosting the market’s growth.
Other News
GE HealthCare recently announced that its Photonova Spectra advanced photon-counting computed tomography system has received CE Mark, expanding access to the technology across Europe and other CE Mark-observing markets.
GE HealthCare also announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid Explorer, Vivid Advanced and Vivid Focus — designed to support cardiac imaging and workflow needs across different care settings.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently sporting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.